Second-Generation
Pharmacogenomic Testing
CNSDose™ is a precision medicine solution designed to help healthcare providers make more informed medication decisions through advanced pharmacogenomic insights. By combining clinically relevant pharmacogenomic markers with innovative blood-brain barrier transport information, CNSDose provides a more comprehensive view of factors that may influence medication response.
CNSDose™ has received MolDx coverage for eligible Medicare beneficiaries who meet applicable coverage requirements.
Ethos Laboratories is proud to offer CNSDose nationwide to qualified healthcare providers. Contact our team to learn more about clinical implementation, ordering, and coverage requirements.
Beyond Traditional Pharmacogenomic Testing
Traditional pharmacogenomic tests primarily evaluate genes involved in drug metabolism. While metabolism plays an important role in medication response, it represents only one component of how medications ultimately affect the patient.
CNSDose™ was developed as a second-generation pharmacogenomic solution by combining clinically actionable pharmacogenomic markers with additional genetic information related to medication transport across the blood-brain barrier. This broader approach provides healthcare providers with more comprehensive information to support individualized medication decisions.
Drug Metabolism
Evaluates clinically relevant pharmacogenes that influence how medications are metabolized, helping identify patients who may process certain medications faster or slower than expected.
Blood-Brain Barrier Insights
Includes informational analysis of genes associated with medication transport across the blood-brain barrier, providing additional insight into factors that may influence medication delivery to the central nervous system.*
Clinical Decision Support
Combines pharmacogenomic information into an easy-to-understand clinical report designed to support medication selection and dosing decisions.
Comprehensive Pharmacogenomic Analysis
CNSDose evaluates a carefully selected panel of genes associated with medication metabolism, transport, and pharmacogenomic response.
Drug Metabolism
- CYP2D6
- CYP2C19
- CYP3A4
- CYP1A2
- UGT1A1
- TPMT
- NUDT15
Blood-Brain Barrier
- ABCB1*
- ABCG2*
- ABCC1*
Additional PGx
- CYP2B6
- CYP2C9
- CYP3A5
- DPYD
- SLCO1B1
- VKORC1
- CES1
Traditional PGx Testing vs CNSDose
Traditional PGx Testing
CNSDose
*Blood-brain barrier transport information is provided for informational purposes only and is not currently incorporated into FDA or CPIC prescribing recommendations.
Clinical Applications
Psychiatry
Optimize medication selection for patients receiving antidepressants, antipsychotics, mood stabilizers, anxiolytics, and other psychotropic therapies.
Behavioral Health
Support personalized medication management for patients receiving treatment in behavioral health clinics and integrated behavioral health programs.
Addiction Medicine
Support medication decision-making for patients receiving treatment for substance use disorders and co-occurring behavioral health conditions.
Pain Management
Provide pharmacogenomic insights for medications commonly used in chronic pain management to support individualized prescribing decisions.
Primary Care
Support everyday medication decisions for patients with depression, anxiety, ADHD, chronic pain, and other conditions managed in primary care.
Neurology
Assist providers with pharmacogenomic information that may support individualized medication selection and management for neurological disorders.
Ready to Learn More About CNSDose™?
Whether you're evaluating pharmacogenomic testing for your practice or simply want to better understand CNSDose™, our team is ready to help.
Speak with an Ethos representative to discuss:
Our team is available to answer your questions and guide you through the process.
Speak with an Ethos Representative